KJHP
REGN icon

K.J. Harrison & Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

K.J. Harrison & Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Hold
526
– – 0.05% 194
2026
Q1 		$406K Sell
526
-5,565
-91% -$4.26M 0.07% 185
2025
Q4 		$4.7M Buy
6,091
+2,000
+49% +$1.36M 0.63% 46
2025
Q3 		$2.45M Buy
4,091
+2,090
+104% +$1.18M 0.35% 79
2025
Q2 		$1.05M Buy
+2,001
New +$1.12M 0.17% 119

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

K.J. Harrison & Partners's REGN Position: Q2 2026 in Review

K.J. Harrison & Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 526 shares worth $328K. The position accounts for 0.05% of the portfolio, ranked #194.

K.J. Harrison & Partners first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.7M in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • K.J. Harrison & Partners held 526 shares of Regeneron Pharmaceuticals worth $328K as of Q2 2026.
  • K.J. Harrison & Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.05% of K.J. Harrison & Partners's portfolio in Q2 2026, its #194 holding.
  • K.J. Harrison & Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • K.J. Harrison & Partners's Regeneron Pharmaceuticals position peaked at $4.7M in Q4 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on K.J. Harrison & Partners's 13F filing for Q2 2026, filed 7 Aug 2026.